Ajouter à une liste

Communiqués BIONOMICSSADR Nasdaq

Actions

BNOX

US09063M2052

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 23/12/2024			Varia. 5j.	Varia. 1 janv.
0,2531 ^USD	+4,20 %		-.--%	-

23/07	Neuphoria Therapeutics accepte une offre d'achat par échange d'actions de Scancell	MT
23/07	Scancell accepte de racheter Neuphoria, l'entité fusionnée sera cotée au Nasdaq	AN

Communiqués

23/07	Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing	AQ
29/06	Neuphoria responds to the announcement made by London-listed Scancell Holdings plc	AQ
26/06	Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc	AQ
08/12	Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees	AQ
04/12	Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium	AQ
01/12	Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions	AQ
24/11	Neuphoria Therapeutics Inc. Sends Letter to Stockholders	AQ
11/11	Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value	AQ
27/10/25	Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process	AQ
20/10/25	Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder	AQ
29/09/25	Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates	AQ
04/09/25	Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)	AQ
28/08/25	Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference	AQ
27/05/25	Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting	AQ
20/05/25	Neuphoria Provides First Quarter 2025 Business Updates	AQ
15/04/25	Neuphoria Provides a Review of 2024 and Highlights 2025 Plans	AQ
03/03/25	Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025	AQ
12/02/25	Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Dès maintenant, trouvez facilement les meilleurs investissements de demain !

🔇